These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 19909752

  • 1. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.
    Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, Gschwantler M, Brunner H, Wenisch C, Bischof M, Strasser M, Datz C, Vogel W, Löschenberger K, Steindl-Munda P, Austrian Hepatitis Study Group.
    Gastroenterology; 2010 Feb; 138(2):503-12, 512.e1. PubMed ID: 19909752
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
    Pessôa MG, Cheinquer H, Almeida PR, Silva GF, Lima MP, Paraná R, Lacerda MA, Parise ER, Pernambuco JR, Pedrosa SS, Teixeira R, Sette H, Tatsch F.
    Ann Hepatol; 2012 Feb; 11(1):52-61. PubMed ID: 22166561
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin.
    Fried MW, Jensen DM, Rodriguez-Torres M, Nyberg LM, Di Bisceglie AM, Morgan TR, Pockros PJ, Lin A, Cupelli L, Duff F, Wang K, Nelson DR.
    Hepatology; 2008 Oct; 48(4):1033-43. PubMed ID: 18697207
    [Abstract] [Full Text] [Related]

  • 10. Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan.
    Gill U, Aziz H, Gill ML.
    Int J Infect Dis; 2013 Nov; 17(11):e1017-21. PubMed ID: 23896656
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
    Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, Peters MG, Koziel MJ, Bhan AK, Alston B, Colquhoun D, Nevin T, Harb G, van der Horst C, AIDS Clinical Trials Group A5071 Study Team.
    N Engl J Med; 2004 Jul 29; 351(5):451-9. PubMed ID: 15282352
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.
    Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Solá R, Shafran SD, Barange K, Lin A, Soman A, Zeuzem S, ACCELERATE Investigators.
    N Engl J Med; 2007 Jul 12; 357(2):124-34. PubMed ID: 17625124
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-García J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT, APRICOT Study Group.
    N Engl J Med; 2004 Jul 29; 351(5):438-50. PubMed ID: 15282351
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.
    Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdés A, Martell M, Esteban R.
    Hepatology; 2002 Apr 29; 35(4):930-6. PubMed ID: 11915041
    [Abstract] [Full Text] [Related]

  • 19. Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test.
    Kanda T, Imazeki F, Yonemitsu Y, Mikami S, Takada N, Nishino T, Takashi M, Tsubota A, Kato K, Sugiura N, Tawada A, Wu S, Tanaka T, Nakamoto S, Mikata R, Tada M, Chiba T, Kurihara T, Arai M, Fujiwara K, Kanai F, Yokosuka O.
    J Viral Hepat; 2011 Jul 29; 18(7):e292-7. PubMed ID: 21129130
    [Abstract] [Full Text] [Related]

  • 20. Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons α-2a and α-2b, plus ribavirin.
    Dogan UB, Akin MS, Yalaki S.
    Eur J Gastroenterol Hepatol; 2013 Nov 29; 25(11):1317-20. PubMed ID: 23680912
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.